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Abstract
Chronic kidney disease (CKD) is part of a number of systemic and renal diseases and may reach epidemic proportions over
the next decade. Efforts have been made to improve diagnosis and management of CKD. We hypothesised that combining
metabolomic and proteomic approaches could generate a more systemic and complete view of the disease mechanisms. To
test this approach, we examined samples from a cohort of 49 patients representing different stages of CKD. Urine samples
were analysed for proteomic changes using capillary electrophoresis-mass spectrometry and urine and plasma samples for
metabolomic changes using different mass spectrometry-based techniques. The training set included 20 CKD patients
selected according to their estimated glomerular filtration rate (eGFR) at mild (59.9616.5 mL/min/1.73 m2; n= 10) or
advanced (8.964.5 mL/min/1.73 m2; n= 10) CKD and the remaining 29 patients left for the test set. We identified a panel of
76 statistically significant metabolites and peptides that correlated with CKD in the training set. We combined these
biomarkers in different classifiers and then performed correlation analyses with eGFR at baseline and follow-up after
2.860.8 years in the test set. A solely plasma metabolite biomarker-based classifier significantly correlated with the loss of
kidney function in the test set at baseline and follow-up (r=20.8031; p,0.0001 and r=20.6009; p = 0.0019, respectively).
Similarly, a urinary metabolite biomarker-based classifier did reveal significant association to kidney function (r=20.6557;
p = 0.0001 and r=20.6574; p = 0.0005). A classifier utilising 46 identified urinary peptide biomarkers performed statistically
equivalent to the urinary and plasma metabolite classifier (r=20.7752; p,0.0001 and r=20.8400; p,0.0001). The
combination of both urinary proteomic and urinary and plasma metabolic biomarkers did not improve the correlation with
eGFR. In conclusion, we found excellent association of plasma and urinary metabolites and urinary peptides with kidney
function, and disease progression, but no added value in combining the different biomarkers data.
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Introduction
Chronic kidney disease (CKD) is characterised by progressive
loss of renal function resulting in reduced glomerular filtration.
The condition is categorised into 5 different stages with the final
stage being end-stage renal failure [1]. Although current clinical
analytical methods are accurate in diagnosing advanced kidney
dysfunction, this is not the case for early stages [2]. Most
importantly, tools for predicting the risk of progression towards
end-stage renal failure are lacking and developing accurate
biomarkers for prognosis of CKD progression represents a clinical
challenge. Hence, efforts are directed towards earlier detection
and better prognosis in order to allow for better therapeutic
interventions to slow down or potentially prevent the progression
of the disease in the future [3]. New technologies such as ‘‘omics’’-
based approaches, including proteomics and metabolomics,
provide more insight into disease mechanisms and therefore hold
the potential to improve management of CKD by providing stage-
specific biomarkers [4]. Proteomic methods are widely used to
identify biomarkers in tissues [5] and various other biological
entities including urine [6]. We have recently developed a CKD
classifier based on 273 urinary peptides (CKD273) with high
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specificity and sensitivity for the diagnosis of CKD [7]. In the
course of this study 889 urine samples of healthy volunteers and
patients with CKD were analysed using capillary electrophoresis–
mass spectrometry (CE-MS). The CKD273 classifier performs
better than the currently used markers (i.e. albuminuria and serum
creatinine) in the early diagnosis of diabetic nephropathy [8,9]. In
addition, a recent study used plasma metabolomics to investigate
the decline of the renal function [10] and to predict incident CKD
[11]. The latter study utilised a large cohort comprising of 1434
participants and identified 16 metabolites in the plasma signifi-
cantly associated with CKD via liquid chromatography-mass
spectrometry (LC-MS); 9 of these metabolites performed better
than serum creatinine. In a prospective cohort, a urinary
metabolite-based profile was found to have diagnostic and
monitoring values in CKD [12]. Proteomics and metabolomics
therefore seem to enable displaying CKD stages with high
confidence. However, the potential of the combination of the
two technologies in improving CKD diagnosis has never been
explored so far. We thus hypothesised that proteomic and
metabolomic biomarkers might perform even better when
combined.
In the present study, our aim was to investigate the potential
value of molecular classifiers for CKD that combine urinary and/
or plasma metabolomics with urinary proteomics. The study
cohort comprised a group of patients from mild to moderate and
advanced CKD, classified by the estimated glomerular filtration
rate (eGFR). For this cohort metabolomic and proteomic data
were available and allowed for a direct and uniform comparison of
metabolomic and proteomic traits. Thus, we established a new
proteomic CKD classifier based on this cohort and did not use the
previously established proteomic classifier CKD273. We indeed
established such classifiers and then tested their performance at
baseline and at follow-up after 2.860.8 (mean 6 SD) years.
Patients and Methods
Patients
Some of the data evaluated in this study have already been
described in previous manuscripts [13,14]. During three consec-
utive days, all patients eligible and attending the outpatient clinics
of the hospitals of Se`te and Montpellier, as well as the dialysis unit
in Se`te, were invited to participate in the study. Clinically stable
patients, over 18 years old, who have not been admitted to
hospital for at least 2 months and did not have acute inflammatory
diseases, were included. A total of 49 patients were involved in the
study; of those, 26 had diabetic nephropathy and the remaining 23
had other aetiologies. For evaluation, glomerular filtration rate
(eGFR) was estimated by the simplified MDRD formula [15].
Plasma and urine samples were obtained from all patients.
Fresh, midstream urine was collected and centrifuged; protein and
creatinine concentrations were determined by the hospital
laboratory. Two aliquots of urine were frozen immediately for
proteomic and metabolomic analyses as described below, and
stored at 280uC until analysis. Blood samples were collected in
EDTA-containing tubes. Blood was put on ice and immediately
centrifuged (10 minutes at 20006g or following the tube
manufacturer’s instructions) at 4uC. Plasma was removed and
stored at 280uC until analysis. Urine and plasma samples were
coded and shipped to two laboratories. Samples were unblinded
after receiving results.
The patients were subsequently seen regularly in the outpatient
clinic; clinical and laboratory data were recorded. Patient manage-
ment during the follow-up period was only based on usual clinical
care. When patients did not attend the clinic, data were obtained
from general practitioners. After 2.860.8 years of follow-up,
outcome was obtained from 43 patients. Of those, eight patients
started dialysis and four patients died not being on dialysis.
The study was designed and conducted fulfilling all the
requisites of the French law on the protection of individuals
collaborating in medical research and was in accordance with the
principles of the Declaration of Helsinki. Written informed
consent was obtained from all participants. The data were
handled according to the rules of the CNIL (Centre National
d’Informatique et Liberte´) warranting the respect of privacy.
Sample collection was declared to the French Ministry with the
allocated reference number DC – 2008 – 417 and was approved
by the local ethics committee, the Comite´ de Protection de
Personnes (CPP) of Montpellier. The CPP is based in the
University Hospital of Montpellier [13].
Study design
According to current recommendations [16,17], a training set was
determined and the results were assessed in an independent test set
(Table 1). The training set was selected based on eGFR measure-
ments at baseline of the 49 samples used in this study. The ‘‘mild
CKD’’ group was defined by patients with the highest eGFRs
(59.9616.5 mL/min/1.73 m2; mean6 SD) whereas the ‘‘advanced
CKD’’ group was defined by patients with the lowest eGFRs
(8.964.5 mL/min/1.73 m2; mean 6 SD) (Table 1). The total
sample of the training set was 20 patients equally distributed between
the two groups and the remaining 29 patients constituted the
independent test set in agreement with current recommendations for
clinical biomarker studies [18]. However, as age and gender are two
factors used to calculate eGFR, they were taken into consideration
during study design and the training set was sex and age matched. A
follow-up cohort was provided after 2.860.8 years to investigate the
progression of renal function. Inter-group comparison of the mean
age in the training set was achieved using t-test.
Methods
Metabolome analysis. Targeted metabolome analysis was
performed using the AbsoluteIDQ p180 Kit (BIOCRATES Life
Sciences AG, Innsbruck, Austria). The commercially available
AbsoluteIDQ p180 kits were used according to the manufacturer’s
instructions for the quantitation of amino acids, acylcarnitines,
sphingomyelins, phosphatidylcholines, hexose (glucose), and bio-
genic amines. The fully automated assay was based on PITC
(phenylisothiocyanate)-derivatization in the presence of isotopical-
ly labelled internal standards followed by flow injection analysis
tandem mass spectrometry (FIA-MS/MS) (acylcarnitines, lipids,
and hexose) as well as liquid chromatography (LC)-MS/MS
(amino acids and biogenic amines). Multiple reaction monitoring
(MRM) detection was used for quantitation. Prostaglandins, other
oxidised polyunsaturated fatty acids and bile acids were extracted
in aqueous acetonitrile containing deuterated internal standards
[19]. The metabolites were determined by reverse phase HPLC-
ESI-MS/MS in negative MRM detection mode. For determining
reducing mono-, di- and oligosaccharides, samples were labelled
with 1-phenyl-3-methyl pyrazolone in the presence of internal
standards. The derivative allowed sugars to be isolated, desalted
and concentrated using C18 solid-phase extraction (SPE). Sugar
concentrations were determined by FIA-MS/MS using MRM
mode in positive and negative ion mode. For quantitation of
energy metabolism intermediates from the citrate cycle, glycolysis,
pentose phosphate pathway and urea cycle in the presence of
internal standards, an LC-MS/MS method in MRM mode was
performed. All above described assays used an API4000 QTrap
tandem mass spectrometer instrument with electrospray ionisation
Metabolomic and Proteomic Biomarkers in Chronic Kidney Disease
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(AB Sciex, Concord, Canada) for quantitation. The content of free
and total fatty acids was determined as their corresponding methyl
ester derivatives (FAMEs) using gas chromatography (GC) coupled
with mass spectrometric detection (Agilent 7890 GC/5795 MSD,
Agilent Technologies, Santa Clara, CA, USA) with an electron
impact ion source in SIM mode against external standards after
derivatisation. Where no external standard was available, com-
pounds were measured semi-quantitatively using spectra recorded
in SCAN mode, respective ratios of characteristic ions and the
retention behaviour. The (semi)-quantitation was carried out with
response factors extra- and/or intrapolated from the nearby
eluting compounds having the same number of double bonds.
The concentrations of amino acids, amines, eicosanoides and
bile acids were calculated with Analyst 1.4.2 Software (AB Sciex).
Quantitation of acylcarnitines, lipids and reducing mono- and
oligosaccharides was accomplished by relating peak heights of the
analytes to peak height of the chosen internal standard using the
MetIDQ Software (Biocrates Life Sciences AG). MetIDQ contains
all listed annotated metabolites with settings for validation.
Quantitation of individual FAME (fatty acid methyl ester) was
carried out with reference to the internal standard 18-methylno-
nadecanoic acid with the Agilent ChemStation Enhanced Data
Analysis Software. The API4000 QTRAP was controlled using
Analyst 1.4.2.
Concentrations of all analysed metabolites were corrected for
natural isotope distribution using algorithms developed by
Biocrates and implemented in the MetIDQ software suite [20]
and reported in mM units.
Proteome analysis. Urine samples were prepared as de-
scribed in [7]. Briefly, a 0.7 mL aliquot stored urine was thawed
and diluted with 0.7 mL 2 M urea, 10 mM NH4OH containing
0.02% SDS. Samples were filtered using Centrisart ultracentrifu-
gation filter devices (20 kDa cut-off; Sartorius, Goettingen,
Germany) at 3,000 g until 1.1 mL of filtrate was obtained.
Subsequently, filtrate was desalted using PD-10 column (GE
Healthcare, Sweden) equilibrated in 0.01% NH4OH OH in
HPLC-grade water. Finally, samples were lyophilised and stored at
4uC prior analysis. The proteomics technique used was CE-MS.
Shortly before CE-MS analysis, lyophilisates were re-suspended in
HPLC-grade water to a final protein concentration of 0.8 mg/mL
checked by BCA assay (Interchim, Montlucon, France). CE-MS
analysis was performed as described [7,8,21]. The average
recovery of sample in the preparation procedure was, ,85%
and the limit of detection was, ,1 fmol. Mass resolution was
above 8,000 Da enabling resolution of monoisotopic mass signals
for z#6. After charge deconvolution, mass accuracy was, ,25
ppm for monoisotopic resolution and, ,100 ppm for unresolved
peaks (z.6). The analytical precision of the platform was assessed
extensively [7,21,22].
Proteomics data processing
Mass spectral peaks representing identical molecules at different
charge states were deconvoluted into single masses using
MosaiquesVisu software [23]. Only signals with z.1 observed in
a minimum of 3 consecutive spectra with a signal-to-noise ratio of
at least 4 were considered. Reference signals of 1770 urinary
polypeptides were used for CE-time calibration by locally
weighted regression. For normalisation of analytical and urine
dilution variances, signal intensities were normalised relative to 29
‘‘housekeeping’’ peptides [21,24]. The obtained peak lists char-
acterise each polypeptide by its molecular mass [Da], normalised
CE migration time [min] and normalised signal intensity. All
detected peptides were deposited, matched, and annotated in a
Microsoft SQL database allowing further statistical analysis [25].
For clustering, peptides in different samples were considered
identical if mass deviation was ,50 ppm. CE migration time was
controlled to be below 0.35 minutes after calibration. All data of
the proteomic and metabolomic analyses were included in Table
S2 and Table S3 in File S1.
Statistical analysis and development of high dimensional
classifiers
For biomarker discovery, statistical analysis was performed by
the use of Wilcoxon rank sum test to calculate the p-values. Only
biomarkers that were found at a 70% frequency in either case or
control group were examined. The false discovery rate adjust-
ments of Benjamini-Hochberg [26] were employed to correct for
multiple testing. A p-value less than 0.05 was considered to be
statistically significant. MosaCluster (version 1.7.0) was used to
build a classifier based on support vector machine (SVM) that
allows the classification of samples in the high dimensional data
space [27,28]. MosaCluster calculated classification scores based
on the amplitudes of the CKD biomarkers. Classification is
performed by determining the Euclidian distance (defined as the
SVM classification score) of the vector to a maximal margin
hyperplane. The SVM classifier uses the log transformed
intensities of x features (peptides or metabolites) as coordinates
in a x-dimensional space. It then builds a x-1 dimensional
Table 1. Patients Characteristics.
Training set Test set
‘‘mild CKD’’ ‘‘advanced CKD’’ p-values
n 10 10 29
Age (years) 65.9610.9 70.769.8 0.2767 73.369
Gender (M/F) 7/3 7/3 17/12
Baseline eGFR (mL/min/1.73 m2) 59.9616.5 8.964.5 ,0.0001 29.5615.6
Follow-up eGFR (mL/min/1.73 m2)* 61.2626.2 8.763.1 0.0025 28.1614.5
BMI (kg/ m2) 31.565.9 2964.7 0.3085 29.766.7
Serum creatinine (mmol/L) 110.7627.1 473.76162.2 ,0.0001 232.46136.7
Serum albumin (g/L) 41.662.4 35.563.7 0.0004 38.563.1
CRP (mg/L) 3.463.0 4.964.4 0.3848 4.463.9
*The mean duration of the follow-up study was 2.860.8 years.
doi:10.1371/journal.pone.0096955.t001
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hyperplane that spans this space by performing a quadratic
programming optimisation of a Lagrangian using the training
labels only while allowing for samples to lie on the wrong side of
the plane. For such mistakes in classification the SVM introduces a
cost parameter C. Because non separable problems in low
dimensions may be separable in higher dimensions the SVM uses
the so called Kernel-trick to transform the samples to a higher
dimensional space. MosaCluster uses the standard radial basis
functions as kernel. These functions are just Gaussians with the
parameter gamma controlling their width. The optimal parame-
ters C and gamma are found via e.g. leave one out cross validation
error estimation. There are generally implemented in SVMs in all
popular data mining software, particularly the kernlab cran
contributed R package is a versatile tool for building SVM
based-classifiers [29]. After identification of significant biomarkers
and generation of different classifiers, they were assessed in a test
set to check their performance.
Correlation of CKD classifiers with eGFR
After biomarker identification using the training set, CKD
molecular classifiers were developed and their performance was
assessed. Individual CKD classifier scores were correlated with
eGFR at baseline and follow-up eGFR was used to predict the
progression of the renal function. The test set of 29 patients was
used in multiple correlation analyses using the classification scores
of the different classifiers with baseline eGFR. For the correlation
analysis with the follow-up eGFR after a period of 2.860.8 years,
data from 43 out of 49 patients were available. The analysis was
performed using MedCalc version 8.2.1.0 (MedCalc Software,
Mariakerke, Belgium).
Results
Urine and plasma samples obtained from patients representing
different stages of CKD were divided into two cohorts: a training
set (n=20; Table 1) for biomarker identification and generation of
CKD classifiers and a test set (n=29; Table 1) to asses the classifier
performance. The training set defined according to eGFR
measurements included a ‘‘mild CKD’’ group (59.9616.5 mL/
min/1.73 m2, mean 6 SD; n=10) with patients between mild to
moderate CKD and a second group named ‘‘advanced CKD’’
(8.964.5 mL/min/1.73 m2, mean 6 SD; n=10) with patients in
advanced CKD that were matched for demographic and clinical
data (Table 1). Follow-up data were obtained after 2.860.8 years.
In the training set, the mean eGFR progressed to 61.2626.2 mL/
min/1.73 m2 (mean 6 SD; Table 1) in the ‘‘mild CKD’’ group
and to 8.763.1 mL/min/1.73 m2 (mean 6 SD; Table 1) in the
‘‘advanced CKD’’ group.
Metabolomic and proteomic biomarkers in urine and
plasma
The statistical analysis resulted in the identification of 76
significant biomarkers with p,0.05 (Table S1 in File S1). The
biomarkers included 30 metabolites comprising 17 plasma
metabolites (Figure 1A) and 13 urinary metabolites (Figure 1B)
and 46 peptides (Figure 1C). Serum creatinine, one of the
significant metabolomic biomarker identified in plasma, was
excluded, as it is the major driver in the calculation of the eGFR.
Among the most significant metabolites identified were asym-
metric dimethylarginine (ADMA) and hydroxykynurenine
(Figure 1B, 1C and Table S1 in File S1). ADMA was the only
identified metabolite present in both plasma and urine (Figure 1B
and 1C). While the concentrations of ADMA and acylcarnitines
were higher in the plasma samples of ‘‘advanced CKD’’ compared
to the ‘‘mild CKD’’ group, ADMA concentrations were lower in
the urine of late CKD patients (Figure 1A and B). Of the 46
urinary peptides to be significantly changed in CKD in this small
study, 28 were collagen fragments with collagen type I alpha 1
being the most represented (Figure 1C and Table S1 in File S1).
Eighteen additional non-collagen peptides were associated with
CKD, including uromodulin, beta-2-microglobulin, apolipopro-
tein A-I, CD99 antigen and cadherin (Figure 1C and Table S1 in
File S1). Most of the collagen type I (Figure 1C) and uromodulin
fragments (Figure 1C) were in lower abundance in advanced CKD
while beta-2-microglobulin, apolipoprotein AI and protein S100-
A9 fragments were in higher abundance in advanced CKD
(Figure 1C) in accordance with previous findings [7,8].
Significant metabolite biomarkers associated with CKD were
further combined into classifiers and assessed in the test set. Two
different classifiers were established using metabolite biomarkers:
one classifier incorporating the 17 metabolites from plasma only
named MetaboP and another classifier based only on 13 urinary
metabolite biomarkers named MetaboU. Likewise, a classifier
based on proteomic traits alone was established with the 46
identified peptides in a classifier named Pept.
Correlation of the biomarker based classifiers with
baseline eGFR
To assess the performance of each classifier at characterising the
renal function, a correlation analysis based on the baseline eGFR
was performed. The three classifiers MetaboP, MetaboU and Pept
were significantly correlated with baseline eGFR (r=20.8031,
p,0.0001, Figure 2A; r=20.6557, p = 0.0001, Figure 2B, and
0.7752, p,0.0001, Figure 2C, respectively). Individual compar-
ison of Pept with MetaboU and MetaboP was not significant
(p = 0.3712 and p= 0.7895, respectively).
Assessment of the biomarker based classifiers in
predicting future eGFR
The performance of above-mentioned CKD classifiers at
predicting the progression of renal function was investigated using
the follow-up data from the test set. The classifier MetaboP was
significantly correlated with follow-up eGFR (r= 20.6009,
p = 0.0019, Figure 3A) and the classifier MetaboU also show a
significant correlation (r=20.6574, p = 0.0005, Figure 3B). The
urinary peptide-based classifier was significantly correlated with
the follow-up eGFR (r=20.8400, p,0.0001, Figure 3C). The
individual comparison of Pept with MetaboU and MetaboP
(p = 0.1606 and p=0.0879, respectively) again demonstrated no
significant difference between the classifiers.
Development of a classifier using combination of
metabolomic and proteomic biomarkers
To assess the potential of combining metabolomics and
proteomics data, all identified biomarkers including 17 plasma
metabolites, 13 urinary metabolites and 46 urinary peptides were
unified in one classifier named Pept_MetaboP+U. In the test set,
the classifier Pept_MetaboP+U showed a significant correlation at
baseline eGFR with a correlation coefficient of r=20.7833 (p,
0.0001, Figure 4A). The comparison of correlation coefficients of
Pept_MetaboP+U with MetaboU and MetaboP with baseline
eGFR (p= 0.3328 and p= 0.8472, respectively) demonstrated no
significant difference. Similar observations were made between
Pept_MetaboP+U and Pept at baseline (p = 0.9407).
The classifier Pept_MetaboP+U also revealed a significant
association with follow-up eGFR with a correlation coefficient of
r=20.8061 (p,0.0001, Figure 4B). The comparison of correla-
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tion coefficients of Pept_MetaboP+U with MetaboU and MetaboP
at follow-up (p= 0.2885 and p= 0.1723, respectively) depicted no
significant difference and these observations were also made
between Pept_MetaboP+U and Pept (p = 0.7327).
Discussion
The aim of the present study was to investigate the value of
proteomics and metabolomics in assessing renal function, and to
assess if combining metabolomic and proteomic approaches in one
comprehensive biomarker-based classifier for CKD may be
Figure 1. Regulation of metabolites and peptides. The fold changes of metabolites and peptides ‘‘mild CKD’’ vs. ‘‘advanced CKD’’. A. Plasma
metabolites. B. Urinary metabolites. C. Urinary peptides. C19:0: Nonadecanoic acid. SM C26:1: Sphingomyelin with acyl residue sum C26:1. PC aa
C42:4: Phosphatidylcholine with acyl-alkyl residue sum C42:4. C14:2: Tetradecadienoylcarnitine. cis-C20:1w9: cis-11-Eicosenoic acid. PC aa C42:4:
Phosphatidylcholine with acyl-alkyl residue sum C42:4. C17:0: Heptadecanoic acid. PC aa C42:5: Phosphatidylcholine with acyl-alkyl residue sum
C42:5. C4: Nonanoylcarnitine. C5: Isovalerylcarnitine. ADMA: Asymmetric dimethylarginine. Total DMA: Total dimethylarginine. C9: Nonanoylcarnitine.
C4:1: Butenoylcarnitine. C5-DC(C6-OH): Acylcarnitine. C14:1-OH: 3-Hydroxytetradecenoylcarnitine. dH: Deoxyhexose. HNAc(S2): (N-acetylhexosamine)-
disulfate. C3:1: Propenoylcarnitine. C7-DC: Pimelylcarnitine. H2-dH2: Dihexose-dideoxyhexose. Asn: Asparagine. Leu: Leucine. H1: Hexose. Pro: Proline.
Cit: Citrulline.
doi:10.1371/journal.pone.0096955.g001
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advantageous. We investigated the value of these molecular
markers in a cross sectional design, and their performance in the
prediction of the renal function decline.
Proteomics [7–9] and metabolomics [10–12] have already
demonstrated value in classifying CKD patients. However, the
diagnostic potential of the combination of both approaches has not
been investigated so far. In our study, we examined samples from
49 patients at different stages of CKD. Urine samples were
analysed employing proteomics, and urine and plasma samples
were analysed using metabolomics. We identified a panel of 30
metabolites (17 plasma and 13 urinary metabolites) significantly
different when comparing a training set of patients with early and
with advanced stage CKD. In the same training set 46 peptides
also demonstrated significantly different distribution. We com-
bined these potential biomarkers in different classifiers and then
performed correlation analyses with the baseline and follow-up
eGFR in an independent test set. All three classifiers, plasma
metabolite-based (MetaboP) urinary metabolite-based (MetaboU),
and urinary peptide-based (Pept) correlated very well with eGFR,
with no significant difference between them. Thus, the plasma and
urinary metabolite and the urinary peptide-based classifiers
individually were identified as effective tools associated with CKD.
The prognostic value of the classifiers was assessed based on the
correlation with the follow-up data. The metabolite and peptide-
based classifiers individually showed good performances in the
prediction of future renal function. Although all classifiers
performed equally well there seemed to be a tendency for the
urinary peptide-based classifier to performed better in the
prognostic evaluation than MetaboU and MetaboP (p = 0.1606
and p=0.0879, respectively). However, a larger sample size would
be required to investigate if this difference is in fact significant.
The results indicate that urinary and plasma metabolites and
urinary peptides may provide similar information in the assess-
ment of CKD. However, urinary peptides may demonstrate
superior performance in a larger study [6].
An advantage of this study is that samples from patients
representing all stages of CKD were included, which enabled
identification of potential biomarkers representing the entire range
of changes occurring throughout CKD progression with good
confidence.
Figure 2. Correlation analysis of metabolomic and proteomic based classifier scores with baseline eGFR. The correlation analysis is
performed by using the support vector machine classification scores obtained for the test set with baseline. A. Classifier MetaboP (plasma
metabolites) r=20.8031 and p,0.0001. B. Classifier MetaboU (urinary metabolites) r=20.6557 and p= 0.0001. C. Classifier Pept (urinary peptides)
r=20.7752 and p,0.0001.
doi:10.1371/journal.pone.0096955.g002
Figure 3. Correlation analysis of metabolomic and proteomic based classifier scores with follow-up eGFR. The correlation analysis is
performed by using the support vector machine classification scores obtained for the test set with follow-up eGFR. A. Classifier MetaboP (plasma
metabolites) r=20.6009 and p= 0.0019. B. Classifier MetaboU (urinary metabolites) r=20.6574 and p=0.0005. C. Classifier Pept (urinary peptides)
r=20.8400 and p,0.0001.
doi:10.1371/journal.pone.0096955.g003
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The combination of urinary peptide, urinary metabolite and
plasma metabolite biomarkers in a classifier (Pept_MetaboP+U)
showed a good correlation performance with eGFR at baseline
(r=20.7833, p,0.0001) and follow-up (r=20.8061, p,0.0001).
However, the comparison of single traits classifiers with the
combined classifier showed no significant improvement suggesting
that the combination of proteomics and metabolomics was not of
an added value in our study.
In the current study 46% of the peptides and 26% of the
metabolites identified were also previously reported [7,30] (see
Table S1 in File S1). The limited coverage of the peptides is due to
differences in the study design as mild and advanced CKD
patients were compared to enable identification of good
confidence biomarkers instead of comparing between healthy
and CKD patients. In the case of the metabolites only amino acids
were investigated in the earlier study whereas we analysed amino
acids, acylcarnitines, sphingomyelins, phosphatidylcholines, hex-
ose (glucose), and biogenic amines. Besides mild versus advanced
CKD detection and prediction of progression, the identified
peptides as well as metabolites could potentially provide insight
into the pathology of CKD. Most of collagen peptide fragments,
representing the majority of detected urinary peptides, were
reduced in patients with advanced CKD, which is in good
accordance with previous studies [31,32]. We hypothesise that this
observation may mirror alterations in the extracellular matrix
(ECM) turnover and fibrosis [33]. Renal fibrosis is one of the key
features of CKD [34] and is characterised by ECM accumulation
as a result of both, increased synthesis and reduced degradation of
ECM proteins [35,36]. Reduced abundance of urinary collagen
fragments in CKD patients might thus reflect decreased ECM
turnover. Renal fibrosis associated with CKD is the ultimate end-
point of a cascade of events, including inflammation [37]. The
observed elevation of protein S100-A9, a pro-inflammatory
protein that promotes the migration of phagocytes [38] supports
the presence of inflammatory processes. Urinary levels of
uromodulin were also reduced which is in accordance with the
literature as decreased uromodulin levels are associated with
interstitial fibrosis or tubular atrophy [32].
In regard to metabolites, we observed increases of ADMA,
hydroxykynurenine, and acylcarnitine levels in the plasma and a
decrease of ADMA in the urine that significantly correlated with a
decrease in the eGFR.
The observed changes in ADMA levels are consistent with
previous observations in early and late stage CKD patients [392
42]. In one of these studies, it was shown that plasma and urinary
levels of ADMA could be used to determine the CKD stage as
plasma accumulation and lower urinary excretion pointed towards
advanced CKD stages [43]. ADMA is a metabolite that inhibits
nitric oxide synthase, an enzyme converting L-arginine to L-
citrulline and nitric oxide (NO) [44]. Impaired generation of NO
by accumulation of ADMA contributes to hypertension and in
turn cardiac and renal dysfunction [45,46].
The accumulation of various acylcarnitines in the plasma likely
depicts impaired clearance due to chronic kidney dysfunction,
which is consistent with recent observations [47]. Besides its
function in fatty acid beta oxidation, L-carnitine modulates acyl-
CoA levels through esterification to acylcarnitines, thus preventing
the accumulation of acyl-CoAs generated in excess in renal failure
[48,49]. Excess acyl-CoAs may contribute to renal and cardiac
lipotoxicity [50252]. Hence, the resulting excess acylcarnitines
normally are filtered in the glomerulus and undergo only limited
renal tubular reabsorption compared to free L-carnitine [53256].
Hydroxykynurenine is part of the kynurenine pathway and
generated as a result of tryptophan degradation [57]. Increased
plasma levels of hydroxykynurenine have previously been reported
to be associated with advanced stage CKD [58,59]. The
association of hydroxykynurenine with CKD is not very well
understood. A hypothesis was presented that accumulation of
hydroxykynurenine could be a result of oxidative stress leading to
impaired renal function [60]. In addition, phosphatidylcholine
diacyl C42:5 increased in the plasma of patients with severe renal
impairment. Phosphatidylcholine diacyl C42:5-to-phosphatidyl-
choline acylalkyl C36:0 ratios were found to be associated with the
loss of eGFR in CKD patients in a longitudinal study [10].
In conclusion, we could demonstrate in this study the feasibility
of combining proteomic and metabolomic approaches in the
prediction of renal function. However, we could not demonstrate
an advantage of combining these different omics traits. In contrast,
our data indicate that essentially a solely urinary peptide, urinary
metabolite and plasma metabolite-based approaches may be
sufficient to predict renal function and that combining metabo-
lomics and proteomics may not provide significant added value.
The results also suggest that urinary peptides may be superior in
predicting renal function decline. However, these results are based
Figure 4. Correlation analysis of a combined proteomics and metabolomics based classifier with baseline or follow-up eGFR. A.
Classifier Pept_MetaboP (urinary peptides and plasma metabolites) with baseline eGFR r=20.7833 and p,0.0001. B. Classifier Pept_MetaboP with
follow-up eGFR r=20.8061 and p,0.0001.
doi:10.1371/journal.pone.0096955.g004
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on a small cohort and need to be further reproduced in large
independent cohorts. The results are valid only in the context of
CKD, and the same concept may well be found advantageous in
the diagnosis of other diseases like coronary artery disease.
Supporting Information
File S1 Supporting tables. Table S1, List of significantly
identified biomarkers between ‘‘Mild CKD vs. Advanced CKD’’
at baseline. 46 peptides, 17 plasma metabolites and 13 urinary
metabolites derived from the training set of mild and advanced
CKD at baseline. The statistical and correlation analysis of each
biomarker with the eGFR were performed at baseline. In the
table, the biomarker marker ID, name, type, source, the Spear-
man’s rank correlation coefficient and its p-values, the p-values
from the statistical analysis (Benjamini Hochberg), the comparison
with biomarkers identified in previous CKD studies were
provided. In the ‘‘comparison with CKD studies’’ column, x
indicates that the biomarker was previously identified. Table S2,
Raw data of identified peptides at baseline. The raw data of all 46
peptides were provided at baseline for the 49 patients used in the
study. Each column represents a patient and the patient ID goes
from 1 to 49. Table S3, Raw data of identified metabolites at
baseline. The raw data of all 30 metabolites (17 in the plasma and
13 in the urine) were provided at baseline for the 49 patients used
in the study. Each column represents a patient and the patient ID
goes from 1 to 49.
(XLS)
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